The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Key takeaways of recent quarter & conference call highlights
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The company has started manufacturing the Sputnik Light vaccine
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Key takeaways of recent quarter & conference call highlights
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Subscribe To Our Newsletter & Stay Updated
